Prothena CORP Public LTD CO 10-Q quarterly reports

Prothena Corporation plc reported a significant net loss of $222.5 million for the nine months ended September 30, 2025, driven by R&D wind-downs and a corporate restructuring, while advancing key partnered neurodegenerative programs.

Prothena Corporation plc reported a significant net loss in Q2 2025, driven by the discontinuation of its birtamimab program and a substantial workforce reduction, while advancing its key neuroscience pipeline.

Prothena Corporation plc reports its financial results for the quarter ended March 31, 2025, and provides updates on its clinical development programs.

Prothena Corporation's Q3 2024 report details a significant shift in revenue streams and ongoing clinical trial progress, alongside strategic collaborations.

Prothena Corporation reports a significant increase in revenue for the second quarter of 2024, primarily due to a licensing agreement with Bristol Myers Squibb, while also progressing its clinical programs.

Prothena Corporation's first quarter 2024 results show a net loss of $72.2 million, with increased R&D spending and no collaboration revenue, while the company continues to advance its clinical programs.